SCHEMBL10044364

SCHEMBL10044364

CNC(=O)CSCCCOC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.42
▸ MAPT P10636 2/20 0.42
▸ TSHR P16473 1/20 0.40
▸ LMNA P02545 1/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ RECQL P46063 1/20 0.36
▸ POLB P06746 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.35
▸ HTT P42858 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ TP53 P04637 2/20 0.33
▸ CES2 O00748 1/20 0.33
▸ GMNN O75496 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ BLM P54132 1/20 0.33
▸ HPGD P15428 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ SLC6A3 Q01959 1/20 0.32
▸ GCK P35557 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12417193 0.83 LMNA (0.50) ALDH1A1MAPTTSHRLMNAKMT2A
SCHEMBL10044363 0.78 GMNN (0.55) ALDH1A1MAPTTSHRRECQLPOLB
SCHEMBL12564367 0.77 TSHR (0.58) ALDH1A1MAPTTSHRLMNAKMT2A
SCHEMBL14667434 0.76 HSD17B10 (0.38) ALDH1A1MAPTTSHRLMNARECQL
SCHEMBL14374030 0.76 MVD (0.49) ALDH1A1MAPTLMNAKMT2ATP53
SCHEMBL27787238 0.75 — —
SCHEMBL15945376 0.73 KMT2A (0.48) ALDH1A1MAPTLMNAKMT2AHSD17B10
SCHEMBL14845357 0.73 ALDH1A1 (0.35) ALDH1A1MAPTTSHRRECQLPOLB
SCHEMBL14667409 0.73 MAPT (0.55) ALDH1A1MAPTKMT2APOLBHSD17B10
SCHEMBL18540716 0.73 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420400-B2 System and method for authenticating tablets APDN (B.V.I.), Inc. (US) 2013-04-16 — — US disclosed
US-8415165-B2 System and method for authenticating sports identification goods APDN (B.V.I.), Inc. (US) 2013-04-09 — — US disclosed
US-20120252025-A1 METHODS FOR COVALENT LINKING OF OPTICAL REPORTERS APDN, Inc. 2012-10-04 — — US disclosed
US-8124333-B2 Methods for covalent linking of optical reporters APDN, Inc. (VG) 2012-02-28 — — US disclosed
US-20090075261-A1 SYSTEM AND METHOD FOR AUTHENTICATING TABLETS APDN (B.V.I.) INC. (VG) 2009-03-19 — — US disclosed
US-20090042191-A1 SYSTEM AND METHOD FOR SECURE DOCUMENT PRINTING AND DETECTION APDN (B.V.I.) INC. 2009-02-12 — — US disclosed
US-20090042191-A1 SYSTEM AND METHOD FOR SECURE DOCUMENT PRINTING AND DETECTION APDN (B.V.I.) INC. 2009-02-12 — — US disclosed
US-20080312427-A1 METHODS FOR COVALENT LINKING OF OPTICAL REPORTERS APDN (B.V.I.) INC. 2008-12-18 — — US disclosed
US-20080299559-A1 METHODS FOR AUTHENTICATING ARTICLES WITH OPTICAL REPORTERS APDN (B.V.I.) INC. 2008-12-04 — — US disclosed
US-20080293052-A1 SYSTEM AND METHOD FOR AUTHENTICATING SPORTS IDENTIFICATION GOODS APDN (B.V.I.) INC. 2008-11-27 — — US disclosed
US-20080293052-A1 SYSTEM AND METHOD FOR AUTHENTICATING SPORTS IDENTIFICATION GOODS APDN (B.V.I.) INC. 2008-11-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312427-A1 METHODS FOR COVALENT LINKING OF OPTICAL REPORTERS PCNA, POLL, LIG3 ALDH1A1 1965/4885MAPT 666/4885TSHR 3495/4885
US-20120252025-A1 METHODS FOR COVALENT LINKING OF OPTICAL REPORTERS PCNA, POLL, LIG3 ALDH1A1 1965/4885MAPT 666/4885TSHR 3495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback